BIOMIMETIC THERAPEUTICS, INC.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$55.6M

1,242 transactions

Summary

BIOMIMETIC THERAPEUTICS, INC. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $39.4MSales: $6.5M19 insiders

Date	Insider	Type	Value
2013-03-01	Lynch Samuel Eugene(President and CEO)	F	$704K
2013-03-01	Lynch Samuel Eugene(President and CEO)	M	$354K
2013-03-01	Lynch Samuel Eugene(President and CEO)	M	$177K
2013-03-01	Lynch Samuel Eugene(President and CEO)	M	$0
2013-03-01	Lynch Samuel Eugene(President and CEO)	M	$0
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	Lynch Samuel Eugene(President and CEO)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—
2013-03-01	BULLOCK LAWRENCE E(Chief Financial Officer)	D	—

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

BIOMIMETIC THERAPEUTICS, INC. — Contributions, Lobbying & Contracts | Poliscope